促红细胞生成素：现状
Erythropoietin: current status.
作者信息
Bunn H F
机构信息
Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
出版信息
Yale J Biol Med. 1990 Sep-Oct;63(5):381-6.
Understanding the regulation of red blood cell production has been greatly enhanced by the cloning and expression of the gene for human erythropoietin (Epo) and its receptor. The availability of recombinant human erythropoietin (rhEpo) for administration to patients has ushered in a new era in molecular medicine. Intravenous or subcutaneous administration of rhEpo can reliably cure the anemia of chronic renal failure and may be effective in the treatment of anemias secondary to chronic inflammation, malignancy, and marrow suppression from chemotherapy. In addition, rhEpo therapy will probably play a prominent role in transfusion medicine, both in preparing patients for auto-transfusions as well as in minimizing red cell transfusion requirements in the post-operative period.
人类促红细胞生成素（Epo）及其受体基因的克隆与表达，极大地增进了我们对红细胞生成调节机制的理解。重组人促红细胞生成素（rhEpo）可用于患者给药，这开创了分子医学的新纪元。静脉注射或皮下注射rhEpo能够可靠地治愈慢性肾衰竭所致的贫血，对于治疗继发于慢性炎症、恶性肿瘤以及化疗引起的骨髓抑制的贫血可能也有效果。此外，rhEpo疗法在输血医学中可能会发挥重要作用，既可为患者自身输血做准备，也能在术后尽量减少红细胞的输血需求。
Zotero 插件